Skip to main content

Vericel Value Stock - Dividend - Research Selection

Vericel

ISIN: US92346J1088 , WKN: A12FU4

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure. The company also markets Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. In addition, it develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Vericel’s Strong Q1 Performance and Growth Potential Affirm Buy Rating

2024-05-10
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Vericel Corporation (NASDAQ:VCEL) Q1 2024 Earnings Call Transcript

2024-05-09
Vericel Corporation (NASDAQ:VCEL) Q1 2024 Earnings Call Transcript May 8, 2024 Vericel Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, thank you for standing by. Welcome to Vericel’s First Quarter 2024 Conference Call. At this time, […]

Vericel First Quarter 2024 Earnings: Beats Expectations

2024-05-09
Vericel ( NASDAQ:VCEL ) First Quarter 2024 Results Key Financial Results Revenue: US$51.3m (up 25% from 1Q 2023). Net...

Vericel Corp (VCEL) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ...

2024-05-09
Vericel reports significant revenue increases and strategic initiatives, setting a positive trajectory for 2024.

Vericel price target raised by $5.60 at Ladenburg, here's why

2024-05-09
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Vericel price target raised by $2 at H.C. Wainwright, here's why

2024-05-09
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Critical Insights From Vericel Analyst Ratings: What You Need To Know

2024-05-09
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Q1 2024 Vericel Corp Earnings Call

2024-05-09
Q1 2024 Vericel Corp Earnings Call

Vericel Corporation 2024 Q1 - Results - Earnings Call Presentation

2024-05-08

Vericel Corporation (VCEL) Q1 2024 Earnings Call Transcript

2024-05-08
Vericel Corporation (NASDAQ:NASDAQ:VCEL) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ETCompany ParticipantsEric Burns - Vice President of Finance...